Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 13,338	$ 7,698	$ 30,460	$ 24,673
General and administrative	6,898	4,688	18,371	14,540
Total operating expenses	20,236	12,386	48,831	39,213
Loss from operations	(20,236)	(12,386)	(48,831)	(39,213)
Other income (expense):
Interest and investment income	2,527	437	7,404	706
Other expense, net	(18)	(48)	(54)	(64)
Total other income, net	2,509	389	7,350	642
Net loss	$ (17,727)	$ (11,997)	$ (41,481)	$ (38,571)
Net loss per share attributable to common shareholders - basic	$ (0.63)	$ (0.87)	$ (1.48)	$ (2.91)
Net loss per share attributable to common shareholders - diluted	$ (0.63)	$ (0.87)	$ (1.48)	$ (2.91)
Weighted-average common shares outstanding used in net loss per share - basic	28,040,173	13,742,385	28,002,663	13,261,422
Weighted-average common shares outstanding used in net loss per share - diluted	28,040,173	13,742,385	28,002,663	13,261,422